Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:ALKS NASDAQ:MEDP NASDAQ:OMCL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.98-2.0%$5.78$4.00▼$7.54$405.80M1.341.43 million shs1.63 million shsALKSAlkermes$51.94-3.4%$43.75$25.17▼$55.67$8.96B0.342.51 million shs1.69 million shsMEDPMedpace$538.23+0.5%$467.24$306.70▼$628.92$15.29B1.15312,395 shs177,537 shsOMCLOmnicell$44.92-1.5%$42.24$26.84▼$55.00$2.07B0.96714,968 shs435,061 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.97%+9.06%+30.22%+42.16%+19.73%ALKSAlkermes-3.42%-4.84%+18.48%+55.70%+73.25%MEDPMedpace+0.51%-3.47%+15.57%+9.06%+67.70%OMCLOmnicell-1.47%+4.39%+17.65%+30.58%+50.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.98-2.0%$5.78$4.00▼$7.54$405.80M1.341.43 million shs1.63 million shsALKSAlkermes$51.94-3.4%$43.75$25.17▼$55.67$8.96B0.342.51 million shs1.69 million shsMEDPMedpace$538.23+0.5%$467.24$306.70▼$628.92$15.29B1.15312,395 shs177,537 shsOMCLOmnicell$44.92-1.5%$42.24$26.84▼$55.00$2.07B0.96714,968 shs435,061 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.97%+9.06%+30.22%+42.16%+19.73%ALKSAlkermes-3.42%-4.84%+18.48%+55.70%+73.25%MEDPMedpace+0.51%-3.47%+15.57%+9.06%+67.70%OMCLOmnicell-1.47%+4.39%+17.65%+30.58%+50.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.67Moderate Buy$19.00172.21% UpsideALKSAlkermes 2.72Moderate Buy$49.63-4.46% DownsideMEDPMedpace 2.07Hold$469.17-12.83% DownsideOMCLOmnicell 2.78Moderate Buy$59.8633.25% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, ABEO, MEDP, and OMCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026MEDPMedpace Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$477.00 ➝ $547.007/7/2026MEDPMedpace Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$490.00 ➝ $515.007/7/2026OMCLOmnicell Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/2/2026MEDPMedpace Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)7/2/2026ALKSAlkermes MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $65.006/29/2026ABEOAbeona Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/29/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$44.00 ➝ $65.006/29/2026ALKSAlkermes Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform6/24/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $61.006/22/2026ALKSAlkermes TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $50.006/18/2026ALKSAlkermes HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M68.35N/AN/A$2.94 per share2.37ALKSAlkermes$1.48B5.87$1.62 per share32.12$11.02 per share4.71MEDPMedpace$2.53B6.08$17.10 per share31.48$16.30 per share33.02OMCLOmnicell$1.18B1.72$2.73 per share16.48$27.45 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$0.977.20N/AN/AN/A-53.98%-38.52%8/13/2026 (Estimated)ALKSAlkermes$241.66M$0.9057.71179.10N/A9.78%9.26%5.66%7/28/2026 (Estimated)MEDPMedpace$451.12M$15.9133.8329.032.7217.19%120.89%24.79%7/22/2026 (Confirmed)OMCLOmnicell$2.05M$0.44102.0933.271.181.67%4.00%2.46%7/30/2026 (Estimated)Latest ALKS, ABEO, MEDP, and OMCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026OMCLOmnicell$0.48N/AN/AN/A$310.25 millionN/A7/28/2026Q2 2026ALKSAlkermes-$0.04N/AN/AN/A$458.98 millionN/A7/22/2026Q2 2026MEDPMedpace$3.98N/AN/AN/A$690.66 millionN/A5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.33-$0.30+$0.03-$0.30$4.57 million$8.72 million4/28/2026Q1 2026OMCLOmnicell$0.33$0.55+$0.22$0.25$304.02 million$309.88 million4/22/2026Q1 2026MEDPMedpace$3.74$4.28+$0.54$4.28$697.82 million$706.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AMEDPMedpaceN/AN/AN/AN/AN/AOMCLOmnicellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.035.895.70ALKSAlkermes0.852.271.70MEDPMedpaceN/A0.850.85OMCLOmnicell0.131.501.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ALKSAlkermes95.21%MEDPMedpace77.98%OMCLOmnicell97.70%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics7.10%ALKSAlkermes4.59%MEDPMedpace20.50%OMCLOmnicell2.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.99 million52.95 millionOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableMEDPMedpace6,20028.56 million22.71 millionOptionableOMCLOmnicell3,58045.48 million44.15 millionOptionableALKS, ABEO, MEDP, and OMCL HeadlinesRecent News About These CompaniesShould You Continue to Hold OMCL Stock in Your Portfolio Now?July 9 at 3:21 PM | zacks.comOmnicell (NASDAQ:OMCL) Stock Rating Lowered by Zacks ResearchJuly 9 at 7:35 AM | marketbeat.comOmnicell (NASDAQ:OMCL) Leadership Move Puts Automation BackJuly 7, 2026 | kalkinemedia.comKWhat's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?July 7, 2026 | zacks.comBurney Co. Invests $7.12 Million in Omnicell, Inc. $OMCLJuly 7, 2026 | marketbeat.comOmnicell, Inc. $OMCL is Avory & Company LLC's 9th Largest PositionJuly 7, 2026 | marketbeat.comPeregrine Capital Management LLC Has $4.50 Million Stock Position in Omnicell, Inc. $OMCLJuly 2, 2026 | marketbeat.comAssenagon Asset Management S.A. Lowers Stake in Omnicell, Inc. $OMCLJuly 2, 2026 | marketbeat.comOmnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Buy" from AnalystsJuly 2, 2026 | americanbankingnews.comOmnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of "Buy" by BrokeragesJuly 2, 2026 | marketbeat.comOmnicell Elevates COO Nnamdi Njoku to PresidentJuly 1, 2026 | tipranks.comNnamdi Njoku Appointed President of OmnicellJuly 1, 2026 | businesswire.comWhy Omnicell (OMCL) is a Top Value Stock for the Long-TermJune 30, 2026 | zacks.comOMCL or HIMS: Which Is the Better Value Stock Right Now?June 26, 2026 | zacks.comDo Options Traders Know Something About Omnicell Stock We Don't?June 24, 2026 | zacks.comOMCL vs. HIMS: Which Stock Is the Better Value Option?June 10, 2026 | zacks.comOmnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?June 10, 2026 | zacks.comOmnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comOmnicell: Why I'm Long Into Q2 Earnings Despite The Bookings WobbleJune 9, 2026 | seekingalpha.comOmnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services BusinessJune 8, 2026 | businesswire.comOmnicell Shareholders Back Governance Amendment And Long Term Growth FocusJune 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026SMRs Spark a Chain Reaction for Nano NuclearBy Jeffrey Neal Johnson | July 2, 2026Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and MastercardBy Jeffrey Neal Johnson | July 9, 2026ALKS, ABEO, MEDP, and OMCL Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.98 -0.14 (-1.97%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$7.01 +0.03 (+0.37%) As of 07/10/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Alkermes NASDAQ:ALKS$51.94 -1.84 (-3.42%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$51.28 -0.66 (-1.27%) As of 07/10/2026 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Medpace NASDAQ:MEDP$538.23 +2.73 (+0.51%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$538.09 -0.14 (-0.03%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Omnicell NASDAQ:OMCL$44.92 -0.67 (-1.47%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$44.99 +0.07 (+0.15%) As of 07/10/2026 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
